The Turkish CRC market
will grow at 4% annually between 2012-2017 and the number of CRC incident cases
will almost double between 2012-2022. Growing CRC population, entry of several
promising new agents and persistent use of branded agents are the key factors
driving this market. In this report, we examine the trends within Turkey’s CRC pharmaceutical
market, which is characterized by the wide use of KRAS testing,
universal healthcare, high patient shares for targeted therapies, the anticipated
launch of several emerging therapies, and Turkish government’s stringent price
Primary research: 73 oncologists surveyed across Turkey. Separate in-depth interviews with 8 Turkish oncologists.
Epidemiology: Total incident cases of CRC in Turkey over a ten-year period (2012-2022) by age, stage, gender, and localization.
Current therapies and medical practice: Reporting use of brands and generics for the CRC treatments available in Turkey.
Pricing and reimbursement: Prices of CRC therapies in Turkey versus other major markets and analysis of the impact of government reimbursement on treatment trends.
Market forecast features: Our analysis evaluates rates of CRC progression and rates of drug treatment with CRC therapies, across all stages of the disease. We include a detailed forecast of current and emerging therapies within platinum agents, antimetabolites, topoisomerase inhibitors, angiogenesis inhibitors, and EGFR inhibitors from 2012 through 2017, using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.